Leo Pharma unfazed by biological competition
A slew of new biological drugs to treat psoriasis are about to enter the market, but it is not something that keeps Denmark’s Leo Pharma up at night.
BY STEFAN SINGH KAILAY
Competition is likely to intensify for the Danish drug company Leo Pharma in the near future. Eli Lilly is the latest contender to announce its entry onto the psoriasis market with a biological drug to treat the inflammation disease with its antibody-treatment ixekizumab, but it does not worry the Danish group too much.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Leo Pharma buys discovery from Danish hospital
For abonnenter
Flagships keep scientists in Denmark
For abonnenter
